MRTX

Stats

Summary

mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.

Market Cap: 4.13 Billion

Primary Exchange: NASDAQ

Website: https://www.mirati.com/

Shares Outstanding: 70.1 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.5427051298212872

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 1005 trading days

From: 2020-12-10 To: 2024-01-04

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor